Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"PRNewsWire • 10/20/23
Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsPRNewsWire • 10/04/23
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLCGlobeNewsWire • 09/21/23
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory AffairsPRNewsWire • 08/22/23
Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung CancerPRNewsWire • 08/10/23
Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPRNewsWire • 07/21/23
Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPRNewsWire • 07/19/23
Genprex Signs Exclusive License to Additional Diabetes Technology with the University of PittsburghPRNewsWire • 07/18/23
Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug CandidateAccesswire • 07/11/23
Genprex granted Chinese patent for lead drug candidate REQORSA with PD-1 antibodies to treat cancersProactive Investors • 07/05/23
Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat CancersPRNewsWire • 07/05/23
Genprex shares rise as FDA grants third Fast Track Designation for small cell lung cancer therapeutic REQORSAProactive Investors • 06/28/23
Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung CancerPRNewsWire • 06/28/23
Genprex (NASDAQ:GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical TrialAccesswire • 06/02/23
Genprex wins approval to advance Phase 2 expansion of Acclaim-1 trial of REQORSA combined with Tagrisso in advanced non-small cell lung cancerProactive Investors • 05/30/23
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung CancerPRNewsWire • 05/30/23
Genprex says positive data from Acclaim-1 clinical trial to be published at 2023 ASCO meetingProactive Investors • 05/26/23
Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual MeetingPRNewsWire • 05/25/23
Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery SystemPRNewsWire • 05/23/23